An overall trend was observed in increasing abundance of measured proteins between screening and day 90, followed by a decline at day 365 ( online supplemental figure 6A ).
← all excerpts
Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma.
1
—
—